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ABSTRACT
Defects in immune reconstitution after hematopoietic stem cell transplantation confer extreme infection risk on to
the transplant recipient. Perturbations in adaptive immune reconstitution have been well characterized, yet defects
in reconstituted innate cellular-mediated immunity remain largely unstudied. Recovery in innate effector cells was
defined by using an establishedmurinemodel of autologous bonemarrow transplantation. Cytokine induction after
cell culture and systemic stimulation with pathogen-associated molecular patterns was also measured for control,
transplant-recipient, and irradiated-only animals. Early reconstitution (7 to 14 days) of donor-derivedmacrophages,
dendritic cells, and polymorphonuclear cells was associated with recovery in interleukin (IL)–12p70 and IL-6
production. Later reconstitution (21 days) of natural killer cells was associated with interferon (IFN)– recovery.
Hence, splenocyte innate cellular-mediated immunity recovered to normal levels in cellularity and IL-12p70,
IFN-, and IFN- production by 21 days after transplantation. In contrast, levels of systemic cytokine production
from transplant-recipient and irradiated-only animals were preserved despite incomplete or absent hematopoietic
reconstitution. These results suggest that innate immune responses to systemic inflammatory challenges are largely
intact after autologous bone marrow transplantation, whereas local innate cellular-mediated immunity within
reconstituting lymphoid organs may be impaired. The disparate effects of autologous hematopoietic stem cell
transplantation on host immune function may translate to differences in susceptibility to local versus systemic
infectious challenges.
© 2004 American Society for Blood and Marrow Transplantation
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Hematopoietic stem cell transplantation (HSCT)
ures many malignant and nonmalignant diseases [1,2]
ut confers signiﬁcant infectious sequelae on to the
ransplant recipient [3] during donor-derived hemato-
oietic engraftment and immune reconstitution [4-6].
usceptibility to infection resulting from adaptive im-
une perturbations is well characterized [2,7-10].
owever, effects of innate cellular immune reconsti-
ution after HSCT remain largely unstudied despite
ncreasing awareness that this arm of immunity has an
mportant role in host defense. w
34The mammalian innate immune system is a ge-
etically predetermined, front-line defense against
nvading pathogens [11]. Cellular components in-
lude natural killer (NK) cells, dendritic cells
DCs), polymorphonuclear cells (PMNCs), macro-
hages, and monocytes. These effector cells are
ctivated upon recognition of pathogen-associated
olecular patterns (PAMPs) through cell-surface
attern-recognition receptors [12]. Toll-like recep-
ors (TLRs) exemplify one such group of evolution-
rily conserved pattern-recognition receptors
hose activation results in innate cytokine induc-
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Reconstituted Innate Immunity
Bion [13,14]. For example, bacterial lipopeptide and
ipopolysaccharide (LPS) activate TLR-2 and
LR-4, respectively, on macrophages to induce in-
erleukin (IL)–12 synthesis, which then stimulates
nterferon (IFN)– production in NK cells [15-17].
n turn, IFN- activates antimicrobial responses,
ncluding enhanced phagocytic function and super-
xide and nitric oxide synthesis [18]. In addition to
heir antimicrobial effects, IL-12 and IFN- also
upport proinﬂammatory T-helper type 1 adaptive
esponses [19]. Like phagocytes, DCs express sur-
ace TLRs that recognize speciﬁc PAMPs [20,21].
or example, DCs are activated by unmethylated
pG oligodeoxynucleotide via cell-surface TLR-9
22]. Once activated, DCs can function as myeloid,
ymphoid, or plasmacytoid effector cells, which pro-
uce cytokines such as IL-12 that invoke microbi-
idal functions through IFN- and support
-helper responses [23]. These critical functions of
nnate cellular-mediated immunity (iCMI) are suf-
cient or necessary for control of infection in nor-
al hosts [24,25].
Defective iCMI is likely to be especially deleteri-
us in HSCT recipients during early reconstitution
hen B and T cell–dependent immunity is absent.
tudies addressing phagocytes, NK cells, and DCs
ave provided some insight into reconstituted iCMI
unction. Quantitatively, phagocytes and NK cells are
he ﬁrst cells to be reconstituted in human transplant
ecipients [5,7,26]. However, reconstituted PMNCs
ave diminished or impaired chemotaxis, superoxide
roduction, and bactericidal activity for at least 2
onths after allogeneic bone marrow transplantation
BMT) [27]. Unlike phagocytes, NK cell number and
unction normalize within 1 month after transplanta-
ion, as measured in human autologous HSCT recip-
ents [28,29]. Reconstitution of donor-derived DCs
ccurs as early as 14 days after transplantation in
atched-sibling allogeneic HSCT [30]. Furthermore,
anipulations in stem-cell source have been shown to
lter this rapidity in DC recovery. For example, DC
econstitution in autologous HSCT patients receiving
nselected bone marrow or peripheral blood stem
ells was 3 times faster than in patients receiving
D34-selected cells [31]. In contrast to cellular recov-
ry, DC function after HSCT remains undeﬁned.
ikewise, little is known about dysfunction in recon-
tituted innate effector cells resulting from impaired
r defective production of accessory-cell cytokines
upporting these effector cells. For example, deﬁcien-
ies in tumor necrosis factor (TNF)– [32] and IL-18
33] may alter PMNC function after HSCT.
These studies were initiated to provide a better
nderstanding of the functional competence and
hysiologic signiﬁcance of innate immune effector
ells and cytokines as they recover after murine autol-
gous BMT. We hypothesized that progressive recov- a
B&MTry in innate effector cells and their cytokine synthetic
apacity would determine functional iCMI reconsti-
ution. We demonstrate that recovery in innate cellu-
ar phenotypes begins early after transplantation, that
ach cell type recovers in stages, and that reconstitu-
ion is nearly complete by 21 days. Coinciding with
his re-emergence in reconstituted splenocyte pheno-
ypes is a phasic recovery of DC and NK cell–derived
ytokines induced in splenocyte culture after PAMP
gonist stimulation. In contrast, systemic cytokine in-
uction after in vivo PAMP challenge was equally
otent early and late after transplantation. Together,
hese results suggest differences in local and systemic
ytokine production that may affect corresponding
nfectious risks in HSCT recipients.
ATERIALS AND METHODS
ice
Female C57BL/6 (B6.SJL-PtprcaPep3b/BoyJ, CD45.2,
y5.1) mice aged 11 to 16 weeks were purchased from
ackson Laboratory (Bar Harbor, ME) and the National
ancer Institute (Frederick,MD).Donormice aged 8 to 12
eeks were congenicC57BL/6CD45.1 (Ly5.2)mice. IL-6
nockout (KO) mice (B6.129S6-Il6tm1Kopf, CD45.2, Ly5.1;
ackson Laboratory) were also used. The Institutional An-
mal Care and Use Committee at Case Western Reserve
niversity approved all animal experiments.
eagents
PAMP agonists used for cytokine induction in-
luded CpG-containing 1826 (5=-TCCATGACGT-
CCTGACGTT; Oligos Etc., Westerville, OR);
on-CpG oligodeoxynucleotide control (ODN-1911;
ligos Etc.); poly(I:C) (Amersham Biosciences, Pisca-
away, NJ); formalin-ﬁxed Staphylococcus aureus Cowan
strain (SAC; Calbiochem, San Diego, CA); and
almonella enteritidis LPS.
utologous BMT
Donor mice femurs and tibias were aspirated, and
one marrow cells were collected sterilely in RPMI
edia, passed through a 250-m ﬁlter, washed once,
nd then resuspended in RPMI media at 1  107cells
er milliliter. Recipient mice were irradiated with 12
y of cesium 137 split-fractionated into 2 equal doses
eparated by 3 hours. After irradiation, recipient mice
ere injected via tail vein with donor bone marrow
ells (5  106 cells in 250 L of Lebovitz media).
Nontransplanted Ly5.1 (CD45.2) C57BL/6 mice
erved as controls. Irradiated-only C57BL/6 animals
ere given split-fraction irradiation without stem-cell
escue. All animals were housed in sterilized microiso-
ator cages and received autoclaved rodent chow. In
ddition, transplant and irradiated-only animals re-
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8eived acid water (pH 2-3) for the ﬁrst 2 weeks after
ransplantation to decrease gut contamination.
eripheral Blood and Splenocyte Harvests
Peripheral blood samples were individually collected
nd processed for each animal within an experimental
roup. Spleens were dissociated by using frosted micro-
cope slides in Hanks balanced salt solution containing
ollagenase IV (400 U/mL; Boerhinger Mannheim, In-
ianapolis, IN) at 37°C for 15 minutes. Red cells were
ysed with hypotonic ACK lysis buffer (150 nmol/L
mmonium chloride, 10 mmol/L potassium carbonate,
nd 0.1 mmol/L ethylenediaminetetraacetic acid
EDTA] adjusted to pH 7.4), and nucleated cells were
ashed and resuspended in Hanks balanced salt solu-
ion/1% fetal calf serum containing 5 mmol/L EDTA.
hese cells were quantiﬁed and then used for both ﬂow
ytometry analysis and cell culture stimulation (de-
cribed below).
Animals were killed at weekly intervals, and
plenocytes from at least 3 mice per experimental
roup were pooled and analyzed by ﬂow cytometry.
rradiated control animals were killed 7 days after
eceiving lethal-dose irradiation without stem cell res-
ue. Preliminary experiments revealed that pooling
as necessary to analyze early harvest times associated
ith low numbers of reconstituted splenocytes.
low Cytometry Analysis
All conjugated monoclonal antibodies (MAb) used
or ﬂow cytometry were purchased from Pharmingen
San Diego, CA). Unselected pooled splenocytes (5 
06 per 100 L of ﬂuorescence-activated cell-sorting
FACS] media) were labeled with anti-FcRII/III MAb
10 g of 2.4 G2/mL) to block nonspeciﬁc labeling due
o FcR binding. Cells were then incubated with ﬂuores-
ein isothiocyanate (FITC) anti-CD45.1MAb (A20) and
ITC anti-CD45.2 (104) to conﬁrm donor engraftment
nd measure residual recipient cells, respectively. After a
0-minute incubation at 4°C, MAb-labeled cells were
ashed 3 times, and streptavidin-peridinin chlorophyll
PerCP) was added for another 20-minute incubation.
rrelevant FITC rat immunoglobulin (Ig)G2a was used
s a negative control for donor and recipient cells. The
ells were again washed and then ﬁxed in 1% formalin
efore analysis by 4-color FACSCalibur (Becton Dick-
nson, Mountain View, CA).
T-, NK-, and B-cell phenotypes were deﬁned by
heir respective stains: APC anti-CD3 (145-2C11), phy-
oerythrin anti-CD49b/Pan-NK (DX5), streptavidin-
erCP/biotin anti-CD19 (1D3), IgM (R6-60.2), or
D45R/B220 (RA3-6B2). PMNCs were distinguished
rom macrophages by using forward- and side-scatter
atterns combined with anti-PMNC MAb (NIMP-R14
34]) and CD11b (M1/70) (Figure 1). Speciﬁcally,
MNCs were deﬁned as CD11bNIMP and macro- p
36hages as CD11bNIMP. DCs were identiﬁed by
PC/major histocompatibility complex class II [I-A/I-E,
G9], phycoerythrin-CD11b, and streptavidin-PerCP/
iotin anti-CD11c (HL3) stains. Streptavidin-PerCP/
y-6G (Gr-1, RB6-8C5) stain was used for further iden-
ifying plasmacytoid DCs and PMNCs.
DC populations were characterized by using side-
nd forward-scatter characteristics after excluding
D3 T-cell and IgM/CD19 B-cell populations
ithin the FL-1 channel.23,35 Speciﬁcally, DCs were
eﬁned as myeloid (CD11cCD11bhigh), lymp-
oid (CD11cCD11bintermediate), and plasmacytoid
CD11cB220Gr-1variable). In addition to CD11b
taining, CD8 staining was used to discriminate be-
ween myeloid (CD11cCD8) and lymphoid
CD11cCD8) DCs (Figure 2).
Fifty thousand events were analyzed per conjugated
Ab condition. Absolute numbers of deﬁned cell pop-
lations were calculated by multiplying the total number
f splenocytes per experimental group with the percent-
ges generated as described previously.
ell Culture Stimulation
Pooled splenocytes were cultured at 1  107/mL in
-cell medium/1% Nutridoma (Boehringer-Mann-
eim, Indianapolis, IN) media consisting of RPMI 1640
nd Dulbecco’s modiﬁed Eagle’s medium (DMEM) in a
:1 ratio and supplemented with 4-(2-hydroxyethyl)-1-
iperazineethanesulfonic acid, l-glutamine, l-arginine,
onessential amino acids, and penicillin/streptomycin
nless otherwise noted. Cells were cultured with media
nly; LPS (1 g/mL); agonistic anti-CD40 (10 g/mL);
nti-CD40 in combination with recombinant IL-4 (20
g/mL) and anti–IL-10 (10 g/mL); CpG-containing
826 (10 g/mL); non-CpG oligodeoxynucleotide con-
rol (10g/mL;ODN-1911); poly(I:C) (50g/mL); and
AC (0.01%). To test for recovery of IFN- synthetic
unction, cells were cultured with combination recom-
inant IL-12 (1 ng/mL) and recombinant IL-18 (3 ng/
L). Conditions were performed in triplicate on sterile
6-well, ﬂat-bottom polypropylene culture plates and
ncubated at 37°C for 24 hours.
nzyme-Linked Immunosorbent Assay
Culture supernatants were assayed for murine IL-6,
L-12p40, and IFN- by using double-sandwich en-
yme-linked immunosorbent assay (ELISA) techniques
s previously described [36]. Murine IL-12p70 (Quan-
ikine M Mouse IL-12p70; R&D Systems, Minneapolis,
N), IFN- (Mouse Interferon Alpha ELISA; PBL
iomedical Laboratories, Piscataway, NJ), TNF-
DuoSet Mouse TNF-; R&D Systems), and IL-10
DuoSet Mouse IL-10; R&D Systems) ELISAs were
erformed according to manufacturer instructions.
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Reconstituted Innate Immunity
Bx Vivo Cellular Depletion
Magnetic-activated cell-sorting (MACS) technol-
gy (Miltenyi Biotec Inc., Auburn, CA) was used to
iscern inducible cytokine sources after cell culture
timulation. Brieﬂy, spleens were extracted and di-
ested in collagenase as described previously. Groups
f 6 control and 9 transplant mice were used to ensure
dequate numbers of splenocytes per harvest time.
plenocytes were washed twice with MACS buffer
phosphate-buffered saline, 50% bovine serum albu-
in, and 5 mol/L EDTA degassed; pH 7.4) and
esuspended at 1  107 cells in 90 L of MACS
uffer. MACS MicroBeads (Miltenyi Biotec) (CD11c,
D11b, CD45, and DX5) were added at concentra-
ions of 10 L of beads per 90 L of splenocyte-
ACS suspension and incubated at 4°C for 15 min-
tes. Cells were washed with MACS buffer,
entrifuged for 10 minutes at 200g, and resuspended
t a concentration of 108 splenocytes per 0.5 mL of
igure 1. Macrophage and polymorphonuclear cell reconstitution.
ransplant recipients (7 and 21 days after transplantation) are il
olymorphonuclear cells (PMN). A hematopoietic-derived (CD45
nd B cells, as indicated by the window (R1), followed by anal
D11bNIMP) and macrophages (CD11bNIMP) were determ
AC and PMN cells, early reconstitution at 7 days contained a
econstitution (see Figure 3 and Table 1 for quantiﬁcations and coACS buffer. Cells were depleted or enriched by S
B&MTsing MidiMacs LS separation columns (Miltenyi Bio-
ec), and the extent of separation was conﬁrmed by
ow cytometry.
n Vivo Challenge with LPS and CpG
ligonucleotides
Where indicated, control, irradiated-only, and
ransplant-recipient mice were injected intraperito-
eally with saline, LPS (250 g), or CpG (150 g).
ndividual sera were collected both before and 5
ours after challenge for ELISA measurement of
ytokines.
tatistical Analysis
Tests for signiﬁcant differences were performed
ith the Mann-Whitney U test for nonparametric
ata and the Student t test for independent mean data.
entative FACS histograms for nontransplant control and syngeneic
d to show enumeration strategies for macrophages (MAC) and
ation was gated to remove FITC-CD3, CD19, and IgM-positive T
CD11b and anti–NIMP-positive cells. PMN cells (deﬁned as
rom 50 000 events. In addition to more donor-derived (CD45.1)
cant population of CD45 cells and nonviable cells versus late
ons).Repres
lustrate
) popul
ysis of
ined f
signiﬁtatistical signiﬁcance was deﬁned as P  .05.
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8ESULTS
econstitution of Innate Immune Effector Cells
fter Murine Autologous BMT
We measured the recovery of innate effector cells in
he spleens of transplanted mice at weekly intervals by
sing FACS analysis, as illustrated for PMNCs, macro-
hages, and DCs (Figures 1 and 2). Total numbers of
plenocytes were dramatically reduced early after trans-
lantation; spleens at 7 days after transplantation con-
ained only 40% as many CD45 cells as control cells
Figure 3). Transplant spleens did not achieve control-
evel cellularity until 3 to 4 weeks after transplantation.
even days after transplantation, donor-derived
CD45.1) splenocytes represented 90% of all hema-
opoietic cells (CD45) at all posttransplant times except
igure 2. Dendritic cell reconstitution. FACS histograms used to e
n control and transplant recipients are illustrated. In control anima
nd CD11c and CD11b were used to deﬁne myeloid (M-DC; C
ubpopulations of dendritic cells. Alternatively, these subtypes were a
s CD11cCD8; myeloid DCs deﬁned as CD11cCD8). F
onor-derived CD45.1 cells (middle and bottom rows; left panels.)
y 21 days after transplantation.ay 7. Although normal spleen contained 2% CD45 e
38ells, 60% of total splenocytes at 7 days were CD45,
nd this population decreased to 5% by 21 days after
ransplantation (Figure 3). In comparison to donor-de-
ived cells, which were large and granular and expressed
yelocytic cell markers on FACS analysis, CD45 cells
n 7-day posttransplantation spleen were large, had little
ide scatter, and did not express common hematopoietic
arkers (negative for CD45R/B220, CD11b, CD11c,
D40, or major histocompatibility complex class II, and
r-1). Irradiated-only spleens contained large numbers
f dead cells but supported small numbers of viable
D45.2 cells, which consisted largely of CD11bmac-
ophages and CD3 T cells. No B-cell, NK cell, or DC
opulations were detectable in irradiated-only mice.
Different populations of hematopoietic cells recov-
te total and myeloid and lymphoid subsets of dendritic cells (DCs)
–B and non–T cells were selected in gate R1 (top row, left panel),
CD11bhigh) and lymphoid (L-DC; CD11cCD11bintermediate/neg)
ally separated by their expression of CD8 (lymphoid DCs deﬁned
splanted mice, the initial gate R1 was modiﬁed to include only
d DCs are absent early (7 days) after transplantation but are presentnumera
ls, non
D11c
ddition
or tran
Myeloired at speciﬁc times after transplantation (Table 1).
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Reconstituted Innate Immunity
BMNCs (CD11bNIMP) recovered ﬁrst, constituting
5% of CD45 cells at 7 days after transplantation but
eclining to10% after day 14, as other cell populations
xpanded. Macrophages (CD11bNIMP) were also
verrepresented at day 7, constituting 35% of donor-
erived cells and having similar declines in frequency as
MNCs. Between 7 and 14 days, B cells
CD45.1B220) expanded rapidly and constituted
0% of total CD45 cells thereafter. T cells (CD3)
ere the last population to recover, increasing between
1 and 60 days after transplantation. These data are
onsistent with other published reports of progressive B-
nd T-lymphocyte reconstitution after autologous BMT
igure 3. Splenocyte reconstitution after syngeneic bone marrow
ransplantation: early innate versus late adaptive recovery. Compos-
te histograms of CD45 splenocyte phenotypes are illustrated for
ontrols and for syngeneic BMT recipients. Percentages of donor
ersus recipient CD45 splenocytes at different recovery times are
ndicated below the ﬁgure. The predominant hematopoietic-de-
ived cellular populations differ at early and late recovery times.
otably, a signiﬁcant CD45 population of splenocytes is present
arly after transplantation (	60% of total splenocytes) but is absent
y 14 days. MAC indicates macrophage; PMN, polymorphonuclear
ells; DC, dendritic cells; NK, natural killer cells.
able 1. Reconstituted Cellular Phenotypes
Cellular Phenotype Control 7 d
cells 98.9  11.1 9.4  1.9†‡
cells 107.4  13.5 2.6  1.0†‡
acrophages 11.2  1.0 17.6  1.5†
olymorphonuclear cells 4.8  1.0 16.9  2.5†
atural killer cells 2.8  0.3 0.7  0.2†‡
endritic cells 3.4  0.2 2.8  0.4‡
ata are mean 
 SEM (106) for donor-derived (CD45.1) sple
independent experiments.
Mean results from 1 experiment.
P  .05 for comparisons between indicated transplantation times
P  .05 for comparisons between 7 days and 21 days after transplantatio
B&MTith unselected bone marrow and puriﬁed stem cells
37,38].
DCs and NK cells reconstituted rapidly in spleens
fter transplantation (Table 1). We quantiﬁed DC
ubpopulations together, because these populations
ere not always distinguishable from one another at
ifferent times of reconstitution. However, we noted a
rend whereby lymphoid DCs were more numerous at
arly times (7 days), whereas myeloid DCs predomi-
ated at subsequent posttransplantation times (Figure
). At 7 days, total DC numbers were similar to those
bserved in normal spleen but comprised 5.6% of
otal CD45 cells—the largest contribution of DCs to
otal splenocytes at any posttransplantation time (Fig-
re 3). For comparison, at 21 days, DCs comprised
.8% of total splenocytes despite being signiﬁcantly
ore numerous than in control animals. Recipient
CD45.2) DCs constituted2% of DCs identiﬁed at
ny posttransplantation time and were not seen in
rradiated-only spleens.
We also studied plasmacytoid DCs, a distinct pop-
lation of DCs (CD11cB220Gr-1) thought to be
esponsible for viral-induced type I IFN production
39]. In comparison to myeloid and lymphoid pheno-
ypes, the number of plasmacytoid DCs expanded to
ontrol levels by 14 days (data not shown). Together,
hese ﬁndings show that DCs recover rapidly and even
xceed normal values, resulting in a relative DC hy-
erplasia that persists well into the ninth week after
ransplantation (Table 1). NK cells demonstrated a
imilar rapid expansion starting at 14 days and even-
ually exceeded control levels by 21 days after trans-
lantation (Table 1).
hasic Recovery of Innate Cytokine Synthesis in
ransplanted Spleen
These studies show that distinct cellular compo-
ents of innate immunity repopulate the spleen in a
eproducible and incremental progression. We next
etermined whether the capacity to produce innate
ytokines from splenocytes recovered in a similar pat-
Time after Transplantation
4 d 21 d 28 d 35 d* 2 mo*
19.1 134  6.8‡ 119.5  38.9 128 108
0.1† 9.9  1.1†‡ 22.3  0† 57.3 104
3.5 19.3  2.6 24.1  1.9† 13.9 19.2
2.8† 16.7  2.0† 6.4  4.6 6.5 6.5
0.2 6.8  1.6†‡ 6.1  1.4† 4.4 5
1.6 7.4  0.7†‡ 9.7  1.3† 6.0 6.6
phenotypes after syngeneic bone marrow transplantation from 4
ntrol (t test)1
75.3 
5.1 
17.7 
14 
2.8 
6.2 
nocyte
and co
n (t test)
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8ern. Spleens from transplanted mice were harvested
t weekly intervals and were cultured with stimuli
nown to induce innate cytokine production. Spleno-
ytes from nontransplant control and irradiated-only
ice were similarly tested. Splenocytes from irradi-
ted-only mice were acquired 7 days after lethal irra-
iation without stem cell rescue.
Interleukin-12p70. We ﬁrst examined IL-12 pro-
uction, given the proximal regulatory importance of
his cytokine in iCMI-mediated responses to infection
nd the well-characterized role of DCs as a source
40]. Compared with control and irradiated-only
pleen cultures, transplant-recipient splenocytes re-
ponded strongly to CpG oligonucleotide, producing
-fold more IL-12p70 starting at 7 days after trans-
lantation (Table 2). This was followed by a gradual
ecline in CpG-induced IL-12p70 that eventually
eached control levels again at 60 days (Figure 4A).
onsistent with a DC source for CpG-induced IL-
2p70 production at day 7, 3-fold depletion of
D11c-expressing cells resulted in a 3-fold reduction
n IL-12p70 synthesis compared with preselected
ransplant splenocytes (8.7
 2.9 pg/mL versus 26.3

.0 pg/mL, respectively; P  .05, Mann-Whitney U
est).
It was possible that these ﬁndings reﬂect macro-
hage or PMNC reconstitution rather than DC re-
overy. Also, an unnatural response produced by re-
ipient cells could not be excluded. Therefore, we
sed a combination of activating anti-CD40 antibody
nd recombinant IL-4 as a more speciﬁc test for DC
roduction of IL-12p70 [41]. These conditions pro-
uced levels of IL-12p70 that were nearly 10-fold
reater than those induced by CpG. Transplanted
pleens again showed rapid recovery of IL-12p70 syn-
hetic capacity by 7 days (Figure 4A). At this post-
ransplantation time, 3-fold depletion in CD11c
able 2. Cytokine Induction after Splenocyte Stimulation
Cytokine Splenocyte Stimulation Contro
L-12p70 (pg/mL) Media 3.6  0.
CpG 6.9  0.
CD40  rIL-4  IL10 53.2  5.
FN- (ng/mL) Media 0.3  0.
SAC 7.5  2.
rIL-12  rIL-18 61.4  19
FN- (pg/mL) Media 10.5  2.
CpG 24.9  6.
Poly(I:C) 66.8  13
L-6 (ng/mL) Media 0.3  0.
LPS 0.3  0
SAC 1.9  0.
CpG 24.9  4.
ata are mean 
 SEM for levels of cytokine measured from cell c
P  .05 for comparisons between speciﬁed animal group and con
P  .05 for comparisons between 7 days after irradiation (XRT)
P  .05 for comparisons between 7 days after BMT and 21 days after B
40plenocytes signiﬁcantly attenuated IL-12p70 induc-
ion after DC-speciﬁc stimulation with CD40/re-
ombinant IL-4 (preselected, 68.7
 8 pg/mL; CD11c
epleted, 13.3 
 2.5 pg/mL; P  .05; Mann-Whitney
test). In addition, the absence of CD40-inducible
L-12p70 in cultures of irradiated-only splenocytes
onﬁrmed that donor-derived DCs were the source of
his cytokine (Table 2). Together, these data show
hat IL-12p70 synthesis recovered at times and in
uantities that correlated with the kinetics and extent
f DC reconstitution in spleen.
Interferon-. IFN- is a key effector cytokine that
ediates necessary antimicrobial functions in the nor-
al host. Because IFN- is a key effector cytokine
roduced by NK cells [16], we predicted that restora-
ion of IFN- synthesis would correlate with both
estored IL-12 competence and the appearance of NK
ells in spleen. Relative to control spleen, 2-fold lower
evels of PAMP-induced IFN- were seen at 7 days
fter transplantation, whereas production was nearly
ndetectable at day 7 after irradiation only, without
ransplantation (Table 2). IFN- synthetic capacity in
esponse to SAC slowly increased to a peak response
t 35 days, at levels that were approximately twice
hose measured from control splenocyte culture (Fig-
re 4B). Because PAMP-induced IL-12p70 peaked as
arly as 7 to 14 days after transplantation, these data
uggest that progressive recovery of NK cells ulti-
ately determined the IFN-–producing ability of
econstituted splenocytes. To this end, direct stimu-
ation of IFN- with combination recombinant IL-12
nd recombinant IL-18 [42] conﬁrmed that IFN-
roductive capacity peaked at later times after trans-
lantation. Consistent with an NK cell source for
FN- after transplantation, 4-fold depletion of
X5 cells in 21-day splenocyte culture nearly abro-
ated recombinant IL-12/recombinant IL-18–stimu-
Animal Group
7 d after XRT 7 d after BMT 21 d after BMT
7.7  2.6 1.5  0.3 4.2  0.6
2.6  1.1*† 37  4.4*†‡ 22.8  1.0*‡
3.9  1.7*† 54  8.9† 37.6  8.2
1.0  0.4 0.2  0 0.3  0.1
0.7  0.2*† 1.4  0.1*†‡ 6.6  0.7‡
0.4  0.2*† 11.9  1.8*†‡ 52.1  11.2‡
45.7  10.9* 32  6.7* 18.6  0.8*
61.1  19.5 93.3  6.8* 107.4  12.7*
56.4  27.4 143  54.4 120.9  48.3
0.2  0.1 0.2  0.1 0.5  0.1
0.2  0.1† 14.1  2.2*†‡ 1.2  0.1*‡
0.3  0.2*† 11.5  0.3*†‡ 3.4  0.5‡
0.2  0.1*† 15.3  1.9*† 10.5  0.7*
supernatants from 4 independent experiments.
est).
ays after bone marrow transplantation (BMT) (t test).l
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Bated IFN- production (2.7 
 0.4 ng/mL after de-
letion versus 34.4 
 2.1 ng/mL in intact spleen; P 
05; Mann-Whitney U test).
Interferon-. Type I IFNs consisting of IFN- and
ultiple species of IFN- mediate critical innate an-
iviral activities [43], regulate inﬂammation in re-
ponse to TLR activation, and may help to induce
ntimicrobial responses dependent on nitric oxide
roduction. The effects of transplantation on type I
FN production have not been well characterized,
espite the relevance of this cytokine to viral infection
n the early posttransplantation period. Therefore, we
easured levels of IFN- from splenocyte cell cul-
ures by using an ELISA that assays multiple IFN-
pecies. In marked contrast to the total loss of IL-12
nd IFN- synthesis in irradiated-only mice, produc-
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igure 4. Induction of IL-12p70 (A), IFN- (B), and IFN- (C)
rom splenocyte cell culture. Mean 
 SD cytokine levels are shown
or control (CL), irradiated-only animals, and transplant-recipient
nimals (days after transplantation) after 24 hours of splenocyte
timulation with PAMP (left) and cell-speciﬁc agonists (right).
plenocytes from irradiated animals were collected and stimulated 7
ays after irradiation. Data from 1 of 4 transplants with similar
esults are shown to illustrate the phasic recovery of control-level,
nducible cytokines from reconstituted splenocytes. Statistical com-
arisons at deﬁned time points with cytokine data pooled from
ultiple time courses are provided in Table 2. Inducible IL-12p70
nd IFN- production occurs in the early posttransplantation pe-
iod (7 days), followed by later IFN- production at 21 days after
ransplantation.ion of SAC- and CpG-inducible IFN- increased t
B&MT-fold in irradiated-only mice (Figure 4C). Both con-
titutive and PAMP-induced IFN- synthesis re-
ained increased until 60 days after transplantation,
hen production returned to control values. Poly(I:C)
lso induces IFN- production, presumably via inter-
ctions with TLR-3 [44]. Irradiated-only and trans-
lanted spleens produced levels of IFN- after poly
:C stimulation comparable to control spleens (Table
). However, at 7 days, reconstituted splenocytes pro-
uced an additional 2- to 3-fold increase in IFN-
hat eventually declined to normal levels by 60 days
fter transplantation. These ﬁndings indicate that
FN- is uniquely regulated relative to other cyto-
ines in the early stages after BMT.
ecovery of Monokine Synthesis by Spleen after
arrow Transplantation
We brieﬂy examined whether other immunoregu-
atory cytokines typically associated with macrophage-
ased innate cellular function [45] reconstituted in
arallel with recovery of innate immune cells. IL-6,
L-10, and TNF- were studied because of their iden-
iﬁed roles in hematopoiesis, inﬂammatory homeosta-
is, or antimicrobial effects [46-48]. At 7 days, IL-6
roduction in response to LPS and SAC was above
ontrol levels; persistent expansion of synthetic ability
as observed until 21 days after transplantation (Ta-
le 2). CpG induction of IL-6 also recovered early
fter transplantation and remained increased through-
ut recovery (Figure 5). IL-10 was produced in a
imilar pattern to IL-6 in response to the same stimuli
data not shown). In contrast to IL-6, TNF- produc-
ion did not exceed control levels after PAMP stimu-
ation until 14 days after transplantation and thereaf-
er remained increased relative to controls in response
0
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igure 5. IL-6 and TNF- induction from reconstituted splenocyte
ell culture. PAMP-inducible cytokine levels (mean 
 SD) are
hown for control (CL), irradiated-only (XRT), and transplant
plenocytes. Splenocytes from irradiated animals were collected and
timulated 7 days after irradiation. Data from 1 of 4 transplants with
imilar results are shown. Early inducible IL-6 and TNF- syn-
hetic production by reconstituted splenocytes was measured.
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8o SAC, LPS, and CpG. No spontaneous production
f these cytokines in media-control cultures was mea-
ured at any harvest time. Irradiated-only splenocytes
ailed to produce these monokines in response to
AMP, thus conﬁrming that donor-derived hemato-
oietic cells were responsible for their production.
ystemic Production of Innate Cytokines Is
reserved after Irradiation and Transplantation
We next assessed the circulating cytokine response
f irradiated mice and transplant recipients after sys-
emic TLR-agonist challenge. In contrast to spleen
ulture, serum cytokine production was remarkably
naffected by irradiation or transplantation (Figure 6).
oth irradiated-only and transplant mice produced
erum levels of IL-12p70 after in vivo PAMP chal-
enge that were comparable to those produced in con-
rol mice. Likewise, both irradiated-only and trans-
lant animals produced normal levels of circulating
FN- after LPS stimulation. In contrast, CpG-in-
uced IFN- responses were 2- to 5-fold lower than
hose induced by LPS. The most profound reduction
as apparent in irradiated-only controls. Patterns of
irculating IL-6 production were similar to those of
FN- in that LPS challenge generated higher sys-
emic cytokine levels than did CpG in all experimental
roups. In contrast, IFN- production was equally
nhanced across irradiated and transplant-recipient
roups after both PAMP and saline challenges; this
uggests that constitutive production of IFN- occurs
n vivo as well as in vitro after irradiation (data not
hown). Together, these results show that irradiation
blates splenic sources of cytokine but has little effect
n extrasplenic sources of in vivo synthesis. Clearly,
ytokine-producing cells survive radiation challenge
or at least 7 days, as has been demonstrated for
acrophages and stromal cells [49-51]. This led us to
ypothesize that splenic and systemic responses after
ransplantation might represent distinct contributions
y donor- and recipient-derived cells, respectively.
isparate Recipient and Donor Cytokine
esponses after Marrow Transplantation
To determine the extent to which donor marrow
ould alter the systemic innate immune response of
ecipients, we performed transplantations with mice
hat were homozygous for intact or disrupted IL-6
enes as either donor or recipient. IL-6 was chosen for
tudy because of its well-deﬁned function in support
f iCMI and its strong systemic induction in trans-
lanted mice. IL-6 KO marrow transplanted into
ild-type (WT) recipients gave rise to cytokine-chi-
eric mice that failed to produce IL-6 in spleen cul-
ure at different times after transplantation (Figure
A) but that generated circulating IL-6 in response to
ndotoxemia in amounts no different than those gen- i
42rated in WT mice transplanted with WT marrow
Figure 7B). WT marrow transplanted into IL-6 KO
ice produced mice that generated IL-6 levels in
pleen comparable to WT/WT transplants, but this
id not produce circulating IL-6 early after transplan-
ation. Small amounts of circulating IL-6 were ob-
erved later after transplantation (day 35). In both
ases, FACS analysis conﬁrmed that 90% of spleno-
ytes were donor derived (data not shown). These data
onﬁrm that systemic cytokine responses induced by
LR agonists are preserved after irradiation and
MT and that they are derived almost entirely from
ells of recipient origin, even after donor-derived cells
nd cytokine function are fully reconstituted in the
pleen.
ISCUSSION
In these studies, we show that lethally irradiated
ice given autologous whole bone marrow rapidly
epopulate their spleens with the major cell types of
nnate immunity, including macrophages, PMNCs,
Cs, and NK cells. Recovery of each cell type was
ollowed by increased cytokine production in response
igure 6. Systemic IL-12p70 (A), IFN- (B), and IL-6 (C) after in
ivo challenge. Mean 
 SD systemic cytokine levels from control
CL), irradiated-only (XRT), and transplant animals 5 hours after
ntraperitoneal challenge with phosphate-buffered saline (Sham),
ipopolysaccharide (LPS), and CpG oligonucleotide are illustrated.
n contrast to phasic recovery of inducible cytokine production
rom cell culture, systemic cytokine production is similar across
osttransplantation times (7 versus 21 days) and animal groups.
ystemic IFN- induction was similarly increased across all exper-
mental groups after TLR challenge (data not shown).
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Bo stimulation with TLR agonists or in response to
CD40 or combined recombinant IL-12 and recom-
inant IL-18, which more speciﬁcally elicit DC and
K cell functions, respectively. DC or NK cell de-
letion by magnetic beads attenuated the respective
roduction of IL-12p70 (day 7) and IFN- (day 21),
urther linking recovery of innate immune function
ith reconstitution of its cellular components. In con-
rast, systemic challenge with LPS induced circulating
ytokine responses whether mice were untreated, were
ethally irradiated, or underwent transplantation. Fur-
hermore, systemic cytokine responses of transplant-
ecipient mice failed to assume the cytokine pheno-
ype of the donated marrow, despite the rapid
ssumption of donor-type cytokine responses by the
pleen. We conclude that the recovery of innate cel-
ular immune function in the intact recipient is more
omplex than would be predicted by studies focused
olely on immune reconstitution of lymphoid tissues.
n particular, radiation-resistant sources of TLR-in-
uced cytokine responses outside the spleen remain
ully capable of mounting systemic inﬂammatory re-
ponses. These ﬁndings not only deﬁne a model of
A Donor-derived IL-6 induction from cell-culture 
B Recipient-derived IL-6 induction after systemic LPS challenge 
Donor:                         WT         KO  WT                               WT          KO         WT 
                                                                  
Recipient:            WT         WT         KO       WT          WT         KO
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igure 7. IL-6 induction in cell culture (A) and after LPS challenge
B): hematopoietic versus systemic disassociation. Mean 
 SD IL-6
evels were compared among nontransplant control (CL) mice and
groups of syngeneic transplant mice (A-C): group A wild-type
WT) mice received WT marrow; group B WT mice received IL-6
O marrow; and group C IL-6 KO mice received normal marrow.
wenty-one days after syngeneic chimeric transplantation, there
ere similar differences in ex vivo and systemic IL-6 cytokine
nduction among the 3 transplant groups (data not shown). In
ddition, FACS data revealed similar spleen composites for all
ransplant groups at each harvest time. However, group B mice had
-fold decreases in total numbers of reconstituted splenocytes rel-
tive to other transplant groups (data not shown).nnate immune reconstitution for further mechanistic p
B&MTnd immunotherapeutic study, but also identify a crit-
cal role for nonlymphoid tissues as sufﬁcient and
mportant sources of circulating cytokines in response
o endotoxemia.
Our murine model demonstrated that iCMI re-
onstitution follows a rapid and reproducible pattern
fter autologous BMT. We chose to use autologous
onors to avoid graft-versus-host disease–associated
ffects on iCMI recovery that would be inherent in an
llogeneic model of transplantation. Donor-derived
ytokine sources were conﬁrmed by the absence of
ytokine response in irradiated-only spleen, by the
aucity of iCMI cells bearing the recipient CD45.2
arker, and by depletion of cytokine responses after
emoval of DCs and NK cells. Key ﬁndings included
he initial recovery of CpG-inducible IL-12p70 in
ynchrony with engraftment of donor DCs in the
pleen and a later increase in production of IFN- as
K cells expanded to peak numbers by day 21. Both
nmethylated CpG oligonucleotide, which activates
urine DC function through TLR-9 [22], and com-
ined stimulation with CD40 and recombinant IL-4
41], which speciﬁcally optimizes DC cytokine release,
rovoked early IL-12p70 responses, thus conﬁrming
hat rapid recovery of DCs also restores IL-12 pro-
uction. The persistent increase in IL-12p70 levels
bserved out to 60 days after transplantation may
eﬂect the increased proportions of DCs relative to
ther cell types in transplanted versus normal spleen.
linical settings have observed similar patterns in
arly DC recovery but have not described DC-derived
ytokine induction [30,31]. The subsequent recovery
f IFN- synthesis in spleen followed both the ap-
earance of donor-derived NK cells and the recovery
f IL-12 synthetic function. Incubation with recom-
inant IL-12 and recombinant IL-18 also induced
FN- responses that correlated with the numbers of
K cells present at each harvest point. Although other
ell types can produce IFN- in response to IL-12/
L-18, incubation of normal spleen with this combi-
ation resulted in intense intracellular staining of
FN- in NK cells and not in T cells or other cell
ypes (data not shown), and DX5-depleted spleen
rom transplant recipients failed to generate IFN-.
FN- synthesis was also restored in response to SAC
nd CpG [52], although at later times. Differences in
he amounts and timing of IFN- production in re-
ponse to SAC or CpG may reﬂect differences in the
elease of IL-12, IL-18, or other cytokines that syn-
rgize for production of IFN- [16,53]. We conclude
hat the IFN- recovers in a second phase of iCMI
econstitution after autologous BMT. This may sig-
ify restoration of antimicrobicidal responses depen-
ent on phagocyte activation by this type II IFN [18].
In contrast to the patterned recovery of DCs and
K splenocytes and their cytokine synthetic capacity,
roduction of the type I IFN, IFN-, was both con-
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8titutive and increased relative to control spleen
hroughout early reconstitution. Remarkably, spleno-
ytes from irradiated-only mice spontaneously pro-
uced increased levels of IFN- relative to control
plenocytes, despite a lack of constitutive or inducible
roduction of other cytokines. Stimulation with the
ouble-stranded RNA reagent, poly(I:C), also induced
mounts of IFN- that were increased above media
ontrol levels in both control and irradiated-only
plenocyte culture but that were increased another
-fold in transplanted spleen from day 7 through day
1. Poly(I:C) activates type I IFN synthesis in a wide
ange of hematopoietic and nonhematopoietic cells.
he observed preservation of IFN- synthesis in ir-
adiated-only spleen more speciﬁcally indicates radio-
esistant cell types as sources, such as macrophages, T
ells, and splenic stromal cells demonstrated to be
resent in these tissues [54,55]. Preliminary attempts
o deﬁne a single cell source instead indicated that
oth CD45 and CD45 cell populations contributed
o production, and this suggests a complex, multicel-
ular response that potentially involves stromal cells
data not shown). Regardless of the cytokine source,
his phenomenon was not limited to spleen alone,
ecause circulating IFN- was similarly increased and
onstitutive in transplanted mice, including irradiat-
d-only mice (data not shown). The biologic conse-
uence of preserved or increased IFN- synthesis in
arly transplantation needs further analysis to deter-
ine whether this mediates signiﬁcant antiviral effects
56,57] or regulates IFN- synthesis, NK cell func-
ion, hematopoietic cell growth, and systemic inﬂam-
atory responses [58-60].
An unexpected ﬁnding was that the systemic cy-
okine response to TLR-activating agents generally
ailed to show a similar pattern of cytokine recovery as
as evident in spleen. Although DC reconstitution
as necessary for recovery of IL-12p70 production in
pleen, transplant recipients generated CpG- and
PS-induced circulating IL-12p70 in amounts similar
o those seen in control animals. This may again
eﬂect the role of radiation-resistant cells, such as
acrophages [61], that are responsive to TLR-4 and
LR-9 and are capable of producing IL-12p70. Other
ystemic cytokine responses were differently affected
y speciﬁc PAMP challenges. For instance, CpG-in-
uced IFN- responses were not seen in irradiated-
nly mice, whereas LPS provoked high levels of cir-
ulating IFN- regardless of transplantation status.
he production of circulating IL-6 was similarly dis-
ociated for CpG and LPS challenges. These ﬁndings
emonstrate a surprising degree of plasticity in the
ystemic cytokine response to TLR-activating agents
hat was not demonstrated in reconstituted spleen.
We further determined that cytokine production
n spleen was almost entirely donor derived by using
eciprocal transplants between IL-6 KO and WT a
4457BL/6 mice. In contrast, systemic IL-6 response
as unaffected by donor IL-6 genotype. Thus, cyto-
ine production by lymphoid organs such as spleen is
trongly dependent on bone marrow–derived and ra-
iation-sensitive cells. Conversely, extrasplenic
ources of IL-6—and, presumably, outside all lym-
hoid tissue—are radiation resistant and unable to
ssimilate iCMI function derived from donor hema-
opoietic stem cells within 35 days. These alternative
ources for IL-6 may include pulmonary and vascular
ndothelium, which can produce signiﬁcant amounts
f cytokines and chemokines after injury or in re-
ponse to LPS [62,63], and tissue macrophages. Con-
istent with a macrophage source of recipient-derived
L-6, CD45.2 peritoneal macrophages were present
nd functional in transplant-recipient and irradiated-
nly animals at 7 days, producing signiﬁcant amounts
f LPS- and CpG-stimulated IL-6 in cell culture (pre-
iminary data). Because systemic and splenic IL-12p70
roduction induced by LPS after transplantation were
imilarly dissociated, circulating IL-12p70 may also be
erived from an unexpected variety of cellular sources,
uch as mesenchymal and stromal cells in bone mar-
ow and spleen [64,65] and progenitor cells in donor
ematopoietic stem cell sources [66,67].
These new ﬁndings suggest that the period of
arly innate reconstitution (up to 21 days after trans-
lantation) may be associated with increased suscep-
ibility to bacterial, viral, and fungal infections as IL-
2–dependent IFN- synthesis recovers. Indeed,
yeloid and lymphoid progenitors originating from
uriﬁed Sca-1/c-kit/Lin hematopoietic stem cells
ave recently been shown to mediate important early
ntimicrobial properties, thus indicating a possible
ole for iCMI-derived cytokines [68,69]. Although
MNCs and macrophages are well represented in the
pleen at 7 days, recovery of IFN- and/or TNF-
ynthesis may be required to optimize the phagocytic
nd antimicrobial function of these cells [70]. How-
ver, these same cytokines will likely be deleterious in
llogeneic transplants because of their ability to accel-
rate graft-versus-host disease [71]. As opposed to
ype II IFN, IFN- production is spontaneous and
ncreased throughout reconstitution, suggesting that
nnate antiviral responses may be reasonably intact
43]. These kinetic and compartmental aspects of cy-
okine recovery after HSCT may have important im-
lications, especially for focal infections such as
plenic candidiasis [72] and pseudomonal pneumonia
73].
In summary, we show that a mouse model of
utologous marrow transplantation can provide novel
nsights into the kinetic and tissue-speciﬁc reconstitu-
ion of functional innate cellular immunity. Our ﬁnd-
ngs conﬁrm the clinical impression that iCMI recov-
rs relatively early after transplantation and provide
dditional information as to how recovered cells func-
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Bion in response to speciﬁc stimuli. We also identify
ifferences in the regulation of type I and type II IFNs
hat may have consequences for both anti-infective
nd antineoplastic responses in the transplant recipi-
nt. Unexpectedly, distinct effects of irradiation and
ransplantation on lymphoid and systemic iCMI func-
ion were identiﬁed. These predict that transplant
ecipients may be fully capable of mounting systemic
nﬂammatory responses to exogenous or endogenous
timuli [74]. These observations have clinical rele-
ance in that they explain why fever responses, which
re highly dependent on cytokine signals, are intact in
he early, pre-engraftment phase of transplantation
ecause of their being recipient in origin [75]. In view
f recent studies that use cytokine promoter geno-
ypes to predict outcome, our studies show that the
ecipient’s cytokine genotype is arguably as important
s the donor’s [76]. If recovery of iCMI can be shown
o increase protection against nosocomial infection,
his model may usefully deﬁne immunotherapies that
ccelerate or enhance iCMI functions that support
ost defense while preventing or suppressing iCMI
unctions that promote graft-versus-host disease.
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